THC Therapeutics, Inc.
THC Therapeutics filed an 8-K disclosing two events: the mutual termination of its June 2025 Share Exchange Agreement with ST Holdings Group due to accounting difficulties, and the creation of 500,000 shares of Series D Convertible Preferred Stock carrying 10 votes per share and convertible at $0.01 per share. The parties remain in discussions about a potential future asset acquisition.
- The Share Exchange Agreement with ST Holdings Group, originally dated June 20, 2025, was mutually terminated on October 30, 2026.
- The termination was attributed to "difficulty in accounting for the transaction."
- The parties are exploring a potential future acquisition of some or all ST Holdings assets.
- 500,000 shares of Series D Convertible Preferred Stock were authorized, each carrying 10 votes per share.
- Each Series D share is convertible into common stock at $0.01 per share.
Price data unavailable.
A failed acquisition blamed on accounting problems combined with a new super-voting, ultra-low-conversion-price preferred class is a double red flag for minority shareholders.
Micro-cap cannabis-adjacent companies frequently use share exchange agreements and preferred stock designations as acquisition currency, but accounting-driven terminations often signal deeper due diligence issues.
The termination was caused by accounting difficulties, which raises questions about the complexity or quality of ST Holdings' financials. The Series D Preferred carries super-voting rights (10:1) and a $0.01 conversion price, creating significant potential dilution for common shareholders.